Raptor Pharma (RPTP) Enrolls First Patient in DR Cysteamine Phase 3
Raptor Pharmaceutical Corp. (Nasdaq: RPTP) announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). In November 2009, Raptor completed its Phase 2b clinical trial...
Get Alerted When News Hits On This Stock - FREE!